KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Change in Inventory (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Change in Inventory for 14 consecutive years, with $4.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Inventory rose 231.16% to $4.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.5 million, a 147.46% increase, with the full-year FY2025 number at $7.5 million, up 147.46% from a year prior.
  • Change in Inventory was $4.2 million for Q4 2025 at Supernus Pharmaceuticals, down from $12.9 million in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $12.9 million in Q3 2025 to a low of -$6.9 million in Q3 2023.
  • A 5-year average of $901200.0 and a median of $1.2 million in 2021 define the central range for Change in Inventory.
  • Peak YoY movement for Change in Inventory: surged 2606.67% in 2021, then crashed 251.42% in 2024.
  • Supernus Pharmaceuticals' Change in Inventory stood at $5.2 million in 2021, then surged by 120.12% to $11.6 million in 2022, then plummeted by 143.52% to -$5.0 million in 2023, then skyrocketed by 36.61% to -$3.2 million in 2024, then surged by 231.16% to $4.2 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Change in Inventory are $4.2 million (Q4 2025), $12.9 million (Q3 2025), and -$4.9 million (Q2 2025).